RxDoctor Payments Data

Ankit Agarwal, MD

Radiation Oncology · Garfield Heights, OHNPI 1629430376

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Teleflex LLC at 25.4% of the total. 2025 is the largest year on record at $1,156, 2.4 times the $485 reported in 2019.

$4,090in general payments, 2019–2025

Across 54 payments — averaging $75.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Palette Life Sciences, Inc.$600
  • Raysearch Laboratories AB (publ)$485
  • Siemens Medical Solutions USA, Inc.$443
  • Theragenics Corporation$384
  • Telix Pharmaceuticals$342
  • plus $797 from 10 others
$14,126in research payments, 2019–2025

Across 1 payment — averaging $14,126 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$14K

What the payments were for

  • Speaking & faculty fees$3509%
  • Food & beverage$3,74091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,090 in reported general payments places this provider in the 85th percentile of 255 radiation oncology providers in Ohio.

See all radiation oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$6,739,275
Medicare patients
984
Services billed
23,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix85$229,245
Tamsulosin Hcl184$2,477
Bicalutamide13$350
Methylprednisolone29$219
Oxybutynin Chloride24$140
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim57$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$30$229,24585 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 radiation oncology providers in Ohio.

Other radiation oncology in Garfield Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →